GBS Venture Partners is a leading Australian life science venture capital firm founded in 1996 and headquartered. See sector focus and contact routes.
GBS Venture Partners is a leading Australian life science venture capital firm founded in 1996 and headquartered in Melbourne. The firm invests in early-stage companies developing human therapeutics, biotechnology, diagnostics, and medical devices, with a geographic focus on Australia, the U.S., and Oceania. GBS typically deploys checks between $10 million and $12 million, though historical data shows an average check of $3.8 million and a maximum of $61 million. The firm backs young businesses to commercialize products that improve patient outcomes while delivering financial returns, often acting as a lead investor in product development startups. Notable portfolio companies include Ivantis, Elastagen, and Moximed, which focus on therapeutic devices and biotech advancements. While the firm maintains a strong track record in life sciences under co-founder and managing partner Brigitte Smith, there is no publicly available distinctive point of view or published writing attributed to the firm in the search results.
Details on this firm come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist comparable investors.
Investors like GBS Venture Partners · Full investor directory · Investor access · Company funding database